Hemorrhagic stroke comprises about 20% of all strokes, with intracerebral hemorrhage
(ICH) being the most common type. Frequency of ICH is increased where hypertension is …

Background Chronic kidney disease (CKD) is an independent risk factor for atrial fibrillation
(AF), which is more prevalent among CKD patients than the general population. AF causes …

Background Andexanet alfa is a modified recombinant inactive form of human factor Xa
developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had …

Abstract Background: The PROTECT AF (WATCHMAN Left Atrial Appendage System for
Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial …

Background Bleeding is a complication of treatment with factor Xa inhibitors, but there are no
specific agents for the reversal of the effects of these drugs. Andexanet is designed to …

Background The benefit of oral anticoagulation in atrial fibrillation is based on a balance
between reduction in ischaemic stroke and increase in major bleeding. We aimed to …

Background In comparison to warfarin, non–vitamin K antagonist oral anticoagulants (NOAC
s) have the advantages of ease of dosing, fewer drug interactions, and lack of need for …

Bleeding is a frequent complication of the management of patients with coronary artery
disease (CAD), especially those presenting with acute coronary syndromes (ACS) or …

Objective: In an international collaborative multicenter pooled analysis, we compared
mortality, functional outcome, intracerebral hemorrhage (ICH) volume, and hematoma …

Background: Several bleeding risk assessment models have been developed in atrial
fibrillation (AF) patients with oral anticoagulants, but the most appropriate tool for predicting …